Evidence map›Paper›PMID 38763444›Full record

ArticleNeurobiology of disease2024

Targeting autophagy impairment improves the phenotype of a novel CLN8 zebrafish model.

Maria Marchese, Sara Bernardi, Asahi Ogi, Rosario Licitra, Giada Silvi, Serena Mero, Daniele Galatolo, Nicola Gammaldi, Stefano Doccini, Gian Michele Ratto and 7 more

Abstract read
In one paragraph

Article in Neurobiology of disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maria MarcheseDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy. Electronic address: maria.marchese2086@gmail.com.
Sara BernardiDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy; Department of Biology, University of Pisa, Pisa, Italy.
Asahi OgiDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy.
Rosario LicitraDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy.
Giada SilviDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy.
Serena MeroDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy.
Daniele GalatoloDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy.
Nicola GammaldiDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy; Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
Stefano DocciniDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy.
Gian Michele RattoNational Enterprise for NanoScience and NanoTechnology (NEST), Istituto Nanoscienze, Consiglio Nazionale delle Ricerche (CNR) and Scuola Normale Superiore, Pisa, Italy.
Simona RapposelliUniversity of Pisa, Department of Pharmacy, Pisa, Italy.
Stephan C F NeuhaussUniversity of Zurich, Department of Molecular Life Sciences, Zurich, Switzerland.
Jingjing ZangUniversity of Zurich, Department of Molecular Life Sciences, Zurich, Switzerland.
Silvia RocchiccioliInstitute of Clinical Physiology, National Research Council, Pisa, Italy.
Elena MichelucciInstitute of Clinical Physiology, National Research Council, Pisa, Italy; Institute of Chemistry of Organometallic Compounds, National Research Council, Pisa, Italy.
Elisa CeccheriniInstitute of Clinical Physiology, National Research Council, Pisa, Italy.
Filippo M SantorelliDepartment of Neurobiology and Molecular Medicine, IRCCS Fondazione Stella Maris, Calambrone, Pisa, Italy. Electronic address: filippo3364@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CLN8 is an endoplasmic reticulum cargo receptor and a regulator of lysosome biogenesis whose loss of function leads to neuronal ceroid lipofuscinosis. CLN8 has been linked to autophagy and lipid metabolism, but much remains to be learned, and there are no therapies acting on the molecular signatures in this disorder. The present study aims to characterize the molecular pathways involved in CLN8 disease and, by pinpointing altered ones, to identify potential therapies. To bridge the gap between cell and mammalian models, we generated a new zebrafish model of CLN8 deficiency, which recapitulates the pathological features of the disease. We observed, for the first time, that CLN8 dysfunction impairs autophagy. Using autophagy modulators, we showed that trehalose and SG2 are able to attenuate the pathological phenotype in mutant larvae, confirming autophagy impairment as a secondary event in disease progression. Overall, our successful modeling of CLN8 defects in zebrafish highlights this novel in vivo model's strong potential as an instrument for exploring the role of CLN8 dysfunction in cellular pathways, with a view to identifying small molecules to treat this rare disease.

Indexed as

AutophagyDisease Models, AnimalNeuronal Ceroid-LipofuscinosesPhenotypeZebrafishZebrafish ProteinsAnimalsAnimals, Genetically ModifiedMembrane ProteinsTrehaloseMembrane ProteinsTrehaloseZebrafish ProteinsAutophagyDrug screeningNeuronal ceroid lipofuscinosis 8Zebrafish

Identifiers

PMID38763444
PMCPMC11163972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.